<DOC>
	<DOCNO>NCT00472849</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose fludarabine cytarabine give combination oxaliplatin rituximab treatment chronic lymphocytic leukemia ( CLL ) , prolymphocytic leukemia , Richter 's transformation . Once high tolerable dose drug combination find , next goal study find combination therapy effective shrink slow growth disease .</brief_summary>
	<brief_title>Oxaliplatin , Fludarabine , Cytarabine , Rituximab Patients With Richter 's Transformation Leukemias</brief_title>
	<detailed_description>Cytarabine design insert DNA ( genetic material cell ) stop DNA repairing . Oxaliplatin design kill cancer cell damage DNA . Fludarabine design make cancer cell less able repair damage DNA . This may increase likelihood cell die . Rituximab design attach lymphoma cell , may cause die . During Phase I portion study , researcher test different dos study drug combination . Oxaliplatin rituximab give dose level . However , fludarabine cytarabine give daily 2 day first 3 participant , daily 3 day next 3 participant , daily 4 day next 3 participant . Although plan treat 3 , 6 participant may treat group . If participant receive fludarabine cytarabine 2 3 day experience intolerable side effect , second cycle may receive next high dose ( additional day fludarabine cytarabine ) follow cycle . Once high tolerate dose fludarabine cytarabine give combination oxaliplatin rituximab find , next group participant enter study take part Phase II portion study . Participants Phase II portion receive study drug high tolerate dose find Phase I portion study . The goal part study look effective drug combination treat patient Richter 's syndrome , prolymphocytic leukemia , aggressive , relapse , refractory CLL . The dose level 4 drug use throughout Phase II portion study , unless intolerable side effect occur . In case , dose may lower treatment may stop . - Each cycle repeat every 4-6 week , depend blood count medical condition . - You receive oxaliplatin needle vein 2 hour Days 1-4 every 28-day study `` cycle . '' - You receive rituximab vein 4-6 hour Day 3 first cycle Day 1 every cycle . - Starting Day 2 , receive fludarabine vein 30 minute cytarabine vein 2 hour 2 , 3 , 4 day . - On Day 6 , receive peg-filgrastim subcutaneously ( needle skin ) help increase white blood cell count . - On day receive study drug , also give fluid ( saline ) vein keep become dehydrate . If receive treatment outpatient , mean visit may take 8 hour . - Additional drug give dose rituximab low risk side effect . If side effect occur , rituximab may stop side effect go away , point drug may restart . This may make time outpatient area longer . - The first study cycle give MD Anderson . Depending response , 5 cycle give either MD Anderson home regular doctor . - Every 1-2 week , blood sample ( 1 teaspoon ) drawn routine test . - At end every cycle , physical exam blood ( 1 teaspoon ) drawn determine whether receive another cycle . - You bone marrow biopsy/aspirate end 3rd 6th cycle . The biopsy end cycle 3 use determine respond treatment determine whether continue receive study drug combination . You may remain study 6 cycle . You take off-study early disease get bad intolerable side effect occur . Once longer receive treatment , end-of-treatment visit . At visit , physical exam blood ( 1 teaspoon ) drawn routine test . If achieve remission , last cycle complete , blood drawn ( 2 teaspoon ) every 3 month routine test . These test continue long remission . This investigational study . Fludarabine , cytarabine , oxaliplatin , rituximab FDA approve commercially available . The use drug together investigational . Up 102 patient take part multicenter study . Up 90 enrol The University Texas ( UT ) MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>All patient histologically cytologically confirm Richter 's transformation , prolymphocytic leukemia , aggressive , relapsed/refractory Bcell chronic lymphocytic leukemia eligible protocol . Patients must 18 year age old . Patients must performance status 02 ( Zubrod scale ) . Patients must adequate renal function ( serum creatinine &lt; = 2 mg/dL creatinine clearance &gt; 50 mL/min ) . Patients renal dysfunction due organ infiltration disease may eligible discussion principal investigator ( PI ) consideration appropriate dose adjustment . Patients must adequate hepatic function ( bilirubin &lt; = 2 mg/dl ; aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; 2.5 * upper limit normal ( ULN ) reference lab unless due leukemia congenital hemolytic disorder [ bilirubin ] ) . Patients hepatic dysfunction due organ infiltration disease may eligible discussion PI consideration appropriate dose adjustment . Female patient childbearing potential ( include &lt; 1 year postmenopausal ) male patient must agree use contraception . Patients must sign informed consent indicate aware investigational nature study . Patients must platelet count &gt; 20,000 , unless low count due disease involvement autoimmune disorder . Untreated uncontrolled lifethreatening infection . Oxaliplatin , fludarabine , cytarabine rituximab intolerance . Pregnancy lactation . Chemotherapy and/or radiation therapy within 4 week . Medical condition , include mental illness substance abuse , deem investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>OFAR 2</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Richter 's Transformation</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
	<keyword>B-Cell Chronic Lymphocytic Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>